Kolexia
Chiche Edmond Hématologie
Chiche Edmond
Hématologie
Hôpital De l'Archet
Nice, France
34 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie aigüe myéloïde Leucémies Leucémie myéloïde Carcinome épithélial de l'ovaire Lymphome malin non hodgkinien Lymphome B Tumeurs de l'ovaire Lymphome B diffus à grandes cellules Seconde tumeur primitive

Collaborateurs

Voir plus
Cluzeau Thomas
Cluzeau Thomas
Hôpital De l'Archet, Nice, France
Loschi Michael
Loschi Michael
Hôpital De l'Archet, Nice, France
Calleja Anne
Calleja Anne
Centre Paoli-Calmettes, Marseille, France
Sammut Rinzine
Sammut Rinzine
CHU Nice, Nice, France

Industries

Voir plus
Janssen
9 collaboration(s)
Dernière en 2023
Sandoz
6 collaboration(s)
Dernière en 2023
Abbvie
3 collaboration(s)
Dernière en 2023
Gilead
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Long-Term Real-World Experience of CPX-351 in Combined French-Italian Cohorts Identified High Rate of Negative Measurable Residual Disease (MRD) and Prolonged Overall Survival
65th ASH Annual Meeting Abstracts   02 novembre 2023
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Clinical cancer research : an official journal of the American Association for Cancer Research   02 décembre 2022
Unmodified Dose of Azacitidine Plus Venetoclax Regimen without Drug Interactions during the First Cycle Leads to Similar Outcomes between Viale-a Clinical Trial and Real-Life in Acute Myeloid Leukemia
Annual Meeting Abstracts 2022   15 novembre 2022
Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al., Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia
Annual Meeting Abstracts 2022   15 novembre 2022
Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience
Annual Meeting Abstracts 2022   15 novembre 2022
New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment.
Bulletin du cancer   15 juin 2022
FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.
International journal of molecular sciences   30 mai 2021
DES Hématologie 2020-2021 : Pathologies du fer (1/2)
Youtube @ Association des Internes en Hématologie AIH   24 mai 2021
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Blood advances   14 mai 2021
CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations (TP53, ASXL1, RUNX1 and EVI1) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort
Blood   13 novembre 2019